Tumor necrosis factor, cancer and anticancer therapy

Cytokine and Growth Factor Reviews

Volumn 16, Issue 1, 2005, Pages 35-53

  Mocellin, Simone ^a   Rossi, Carlo Riccardo ^a   Pilati, Pierluigi ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antineoplastic agent; Antitumor therapy; Tumor necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; BORTEZOMIB; BUTYRIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; ETANERCEPT; GAMMA INTERFERON; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INFLIXIMAB; LIPOSOME; LITHIUM SALT; MELPHALAN; MITHRAMYCIN; MUTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHONIC ACID DERIVATIVE; SALICYLIC ACID; SULINDAC; TRIPTOLIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CARCINOGENICITY; CELL DEATH; CLINICAL TRIAL; COLORECTAL CARCINOMA; CYTOTOXICITY; DRUG INDICATION; DRUG POTENCY; GENETIC POLYMORPHISM; HUMAN; LIVER CELL CARCINOMA; MELANOMA; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; MYELOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR VASCULARIZATION;

EID: 14044261093     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2004.11.001     Document Type: Review

References (222)

1. S. Mocellin, S. Mandruzzato, V. Bronte, M. Lise, and D. Nitti Vaccines for solid tumors Lancet Oncol 5 11 2004 681 689
2. S.A. Rosenberg Principles and practice of the biologic therapy of cancer 2000 Lippincott, Williams & Wilkins
3. K. Pfeffer Biological functions of tumor necrosis factor cytokines and their receptors Cytokine Growth Factor Rev. 14 3/4 2003 185 191
4. E.A. Carswell, L.J. Old, R.L. Kassel, S. Green, N. Fiore, and B. Williamson An endotoxin-induced serum factor that causes necrosis of tumors Proc Natl Acad Sci USA 72 9 1975 3666 3670
5. W. Coley Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases Bull Johns Hopkins Hosp 7 1896 157
6. B. Beutler, D. Greenwald, J.D. Hulmes, M. Chang, Y.C. Pan, and J. Mathison Identity of tumour necrosis factor and the macrophage-secreted factor cachectin Nature 316 6028 1985 552 554
7. K. Takeda, S. Iwamoto, H. Sugimoto, T. Takuma, N. Kawatani, and M. Noda Identity of differentiation inducing factor and tumour necrosis factor Nature 323 6086 1986 338 340
8. T. Shirai, H. Yamaguchi, H. Ito, C.W. Todd, and R.B. Wallace Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor Nature 313 6005 1985 803 806
9. F.J. Lejeune, C. Ruegg, and D. Lienard Clinical applications of TNF-alpha in cancer Curr Opin Immunol 10 5 1998 573 580
10. J. Oppenheim, and M. Feldmann Cytokine reference 2000 Academic Press San Diego
11. M.H. Bemelmans, L.J. van Tits, and W.A. Buurman Tumor necrosis factor: function, release and clearance Crit Rev Immunol 16 1 1996 1 11
12. B. Aggarwal Signaling pathways of the TNF superfamily: a double edged sword Nat Rev Immunol 3 2003 745 756
13. G. Chen, and D.V. Goeddel TNF-R1 signaling: a beautiful pathway Science 296 5573 2002 1634 1635
14. S. Ghosh, and M. Karin Missing pieces in the NF-kappaB puzzle Cell 109 Suppl. 2002 81 96
15. X. Li, Y. Yang, and J.D. Ashwell TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2 Nature 416 6878 2002 345 347
16. M. Leist, and M. Jaattela Four deaths and a funeral: from caspases to alternative mechanisms Nat Rev Mol Cell Biol 2 8 2001 589 598
17. C. Du, M. Fang, Y. Li, L. Li, and X. Wang Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition Cell 102 1 2000 33 42
18. L. Foghsgaard, D. Wissing, D. Mauch, U. Lademann, L. Bastholm, and M. Boes Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor J Cell Biol 153 5 2001 999 1010
19. R.M. Locksley, N. Killeen, and M.J. Lenardo The TNF and TNF receptor superfamilies: integrating mammalian biology Cell 104 4 2001 487 501
20. J.W. Kim, E.J. Choi, and C.O. Joe Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP Oncogene 19 39 2000 4491 4499
21. E.E. Varfolomeev, and A. Ashkenazi Tumor necrosis factor: an apoptosis JuNKie? Cell 116 4 2004 491 497
22. R.Z. Orlowski, and A.S. Baldwin Jr. NF-kappaB as a therapeutic target in cancer Trends Mol Med 8 8 2002 385 389
23. M. Irmler, M. Thome, M. Hahne, P. Schneider, K. Hofmann, and V. Steiner Inhibition of death receptor signals by cellular FLIP Nature 388 6638 1997 190 195
24. M. Jaattela, M. Benedict, M. Tewari, J.A. Shayman, and V.M. Dixit Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells Oncogene 10 12 1995 2297 2305
25. S. Fulda, M.U. Kufer, E. Meyer, F. van Valen, B. Dockhorn-Dworniczak, and K.M. Debatin Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer Oncogene 20 41 2001 5865 5877
26. B.B. Aggarwal Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis JNK and NF-kappaB Ann Rheum Dis 59 Suppl.1 2000 6 16
27. E. Gulbins, and H. Grassme Ceramide and cell death receptor clustering Biochim Biophys Acta 1585 2-3 2002 139 145
28. C. De Nadai, P. Sestili, O. Cantoni, J.P. Lievremont, C. Sciorati, and R. Barsacchi Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide Proc Natl Acad Sci USA 97 10 2000 5480 5485
29. B. Liu, N. Andrieu-Abadie, T. Levade, P. Zhang, L.M. Obeid, and Y.A. Hannun Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death J Biol Chem 273 18 1998 11313 11320
30. N. Fehrenbacher, M. Gyrd-Hansen, B. Poulsen, U. Felbor, T. Kallunki, and M. Boes Sensitization to the lysosomal cell death pathway upon immortalization and transformation Cancer Res 64 15 2004 5301 5310
31. V.A. Polunovsky, C.H. Wendt, D.H. Ingbar, M.S. Peterson, and P.B. Bitterman Induction of endothelial cell apoptosis by TNF alpha: modulation by inhibitors of protein synthesis Exp Cell Res 214 2 1994 584 594
32. A.M. Eggermont, J.H. de Wilt, and T.L. ten Hagen Current uses of isolated limb perfusion in the clinic and a model system for new strategies Lancet Oncol 4 7 2003 429 437
33. M.A. Palladino Jr., M.R. Shalaby, S.M. Kramer, B.L. Ferraiolo, R.A. Baughman, and A.B. Deleo Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity J Immunol 138 11 1987 4023 4032
34. K. Shimomura, T. Manda, S. Mukumoto, K. Kobayashi, K. Nakano, and J. Mori Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity Int J Cancer 41 2 1988 243 247
35. P.A. Van de Wiel, N. Bloksma, C.F. Kuper, F.M. Hofhuis, and J.M. Willers Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity J Pathol 157 1 1989 65 73
36. M. Furrer, H.J. Altermatt, H.B. Ris, U. Althaus, C. Ruegg, and D. Lienard Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system Melanoma Res 7 Suppl.2 1997 S43 S49
37. F.R. Balkwill, A. Lee, G. Aldam, E. Moodie, J.A. Thomas, and J. Tavernier Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons Cancer Res 46 8 1986 3990 3993
38. L.F. Fajardo, H.H. Kwan, J. Kowalski, S.D. Prionas, and A.C. Allison Dual role of tumor necrosis factor-alpha in angiogenesis Am J Pathol 140 3 1992 539 544
39. N. Watanabe, Y. Niitsu, H. Umeno, H. Kuriyama, H. Neda, and N. Yamauchi Toxic effect of tumor necrosis factor on tumor vasculature in mice Cancer Res 48 8 1988 2179 2183
40. P.L. Naredi, P.G. Lindner, S.B. Holmberg, U. Stenram, A. Peterson, and L.R. Hafstrom The effects of tumour necrosis factor alpha on the vascular bed and blood flow in an experimental rat hepatoma Int J Cancer 54 4 1993 645 649
41. J.J. Mule, A. Asher, J. McIntosh, R. Lafreniere, E. Shiloni, and A. Lefor Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy Cancer Immunol Immunother 26 3 1988 202 208
42. B. van Etten, M.R. de Vries, I.M.G. van, T.E. Lans, G. Guetens, and G. Ambagtsheer Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion Br J Cancer 88 2 2003 314 319
43. A.F. Olieman, R.J. van Ginkel, H.J. Hoekstra, E.L. Mooyaart, W.M. Molenaar, and H.S. Koops Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor Ann Surg Oncol 4 1 1997 64 69
44. X. Huang, G. Molema, S. King, L. Watkins, T.S. Edgington, and P.E. Thorpe Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature Science 275 5299 1997 547 550
45. Y. Zhang, Y. Deng, T. Wendt, B. Liliensiek, A. Bierhaus, and J. Greten Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma J Clin Invest 97 10 1996 2213 2224
46. A. Bierhaus, Y. Zhang, Y. Deng, N. Mackman, P. Quehenberger, and M. Haase Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor J Biol Chem 270 44 1995 26419 26432
47. E. Napoleone, A. Di Santo, and R. Lorenzet Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk Blood 89 2 1997 541 549
48. J.C. Lewis, N.L. Jones, M.I. Hermanns, O. Rohrig, C.L. Klein, and C.J. Kirkpatrick Tissue factor expression during coculture of endothelial cells and monocytes Exp Mol Pathol 62 3 1995 207 218
49. P. Vandenabeele, W. Declercq, D. Vercammen, M. Van de Craen, J. Grooten, and H. Loetscher Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma J Exp Med 176 4 1992 1015 1024
50. S.A. Gregory, J.H. Morrissey, and T.S. Edgington Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin Mol Cell Biol 9 6 1989 2752 2755
51. B. Stoelcker, B. Ruhland, T. Hehlgans, H. Bluethmann, T. Luther, and D.N. Mannel Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature Am J Pathol 156 4 2000 1171 1176
52. C. Ruegg, A. Yilmaz, G. Bieler, J. Bamat, P. Chaubert, and F.J. Lejeune Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma Nat Med 4 4 1998 408 414
53. P.C. Brooks, A.M. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, and G. Klier Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 7 1994 1157 1164
54. S. Mocellin, M. Provenzano, C.R. Rossi, P. Pilati, R. Scalerta, M. Lise, and D. Nitti Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to TNF-driven cytotoxicity Clin Cancer Res 10 20 2004 6879 6886
55. E.R. Manusama, P.T. Nooijen, J. Stavast, N.M. Durante, R.L. Marquet, and A.M. Eggermont Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat Br J Surg 83 4 1996 551 555
56. P.T. Nooijen, E.R. Manusama, A.M. Eggermont, L. Schalkwijk, J. Stavast, and R.L. Marquet Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study Br J Cancer 74 12 1908-1915
57. A.L. Seynhaeve, J.H. de Wilt, S.T. van Tiel, A.M. Eggermont, and T.L. ten Hagen Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity Br J Cancer 86 7 2002 1174 1179
58. A.H. van der Veen, J.H. de Wilt, A.M. Eggermont, S.T. van Tiel, A.L. Seynhaeve, and T.L. ten Hagen TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects Br J Cancer 82 4 2000 973 980
59. T.W. Bauer, M. Gutierrez, D.J. Dudrick, J. Li, I.A. Blair, and C. Menon A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan Surgery 133 4 2003 420 428
60. H.R. Alexander Jr., S.K. Libutti, D.L. Bartlett, J.F. Pingpank, K. Kranda, and C. Helsabeck Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy Cancer 95 4 2002 730 736
61. M. Posner, D. Lienard, F.J. Lejeune, D. Rosenfelder, and J.M. Kirkwood Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF) alone for metastatic in-transit melanoma Oncol PAMASC 1994 A1351
62. J. Seong, C.G. Milross, N.R. Hunter, H.C. Shin, and L. Milas Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha Anticancer Drugs 8 1 1997 80 87
63. J.F. Buell, E. Reed, K.B. Lee, R.J. Parker, D.J. Venzon, and K. Amikura Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells Ann Surg Oncol 4 2 1997 141 148
64. F.J. Lejeune Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability J Clin Invest 110 4 2002 433 435
65. J.H. de Wilt, T.L. ten Hagen, G. de Boeck, S.T. van Tiel, E.A. de Bruijn, and A.M. Eggermont Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br J Cancer 82 5 2000 1000 1003
66. L. Duan, M. Aoyagi, M. Tamaki, Y. Yoshino, T. Morimoto, and H. Wakimoto Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor alpha Clin Cancer Res 10 1 Pt 1 2004 234 243
67. K.H. Choi, H.Y. Choi, J.K. Ko, S.S. Park, Y.N. Kim, and C.W. Kim Transcriptional regulation of TNF family receptors and Bcl-2 family by chemotherapeutic agents in murine CT26 cells J Cell Biochem 91 2 2004 410 422
68. H. LeBlanc, D. Lawrence, E. Varfolomeev, K. Totpal, J. Morlan, and P. Schow Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax Nat Med 8 3 2002 274 2781
69. E.A. Havell, W. Fiers, and R.J. North The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity J Exp Med 167 3 1988 1067 1085
70. N.L. Vujanovic Role of TNF family ligands in antitumor activity of natural killer cells Int Rev Immunol 20 3/4 2001 415 437
71. S. Mocellin, M. Provenzano, M. Lise, D. Nitti, and C.R. Rossi Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma Int J Cancer 107 2 2003 317 322
72. A. Prevost-Blondel, E. Roth, F.M. Rosenthal, and H. Pircher Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo J Immunol 164 7 2000 3645 3651
73. C.H. Poehlein, H.M. Hu, J. Yamada, I. Assmann, W.G. Alvord, and W.J. Urba TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells J Immunol 170 4 2003 2004 2013
74. C.N. Baxevanis, I.F. Voutsas, O.E. Tsitsilonis, M.L. Tsiatas, A.D. Gritzapis, and M. Papamichail Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice Eur J Immunol 30 7 2000 1957 1966
75. C.G. Figdor, I.J. De Vries, W.J. Lesterhuis, and C.J. Melief Dendritic cell immunotherapy: mapping the way Nat Med 10 5 2004 475 480
76. F. Balkwill Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13 2 2002 135 141
77. F. Balkwill Cancer and the chemokine network Nat Rev Cancer 4 7 2004 540 550
78. M. Kirstein, and C. Baglioni Tumor necrosis factor stimulates proliferation of human osteosarcoma cells and accumulation of c-myc messenger RNA J Cell Physiol 134 3 1988 479 484
79. S. Wu, C.M. Boyer, R.S. Whitaker, A. Berchuck, J.R. Wiener, and J.B. Weinberg Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression Cancer Res 53 8 1993 1939 1944
80. A. Ferrajoli, M.J. Keating, T. Manshouri, F.J. Giles, A. Dey, and Z. Estrov The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia Blood 100 4 2002 1215 1219
81. R.Y. Liu, C. Fan, G. Liu, N.E. Olashaw, and K.S. Zuckerman Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha supported proliferation of leukemia and lymphoma cell lines J Biol Chem 275 28 2000 21086 21093
82. C. Tselepis, I. Perry, C. Dawson, R. Hardy, S.J. Darnton, and C. McConkey Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action Oncogene 21 39 2002 1071 1081
83. C. Humblet, R. Greimers, P. Delvenne, J. Deman, J. Boniver, and M.P. Defresne Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting J Natl Cancer Inst 88 12 1996 824 831
84. R.J. Moore, D.M. Owens, G. Stamp, C. Arnott, F. Burke, and N. East Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis Nat Med 5 7 1999 828 831
85. A. Komori, J. Yatsunami, M. Suganuma, S. Okabe, S. Abe, and A. Sakai Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation Cancer Res 53 9 1993 1982 1985
86. M. Suganuma, S. Okabe, M.W. Marino, A. Sakai, E. Sueoka, and H. Fujiki Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice Cancer Res 59 18 1999 4516 4518
87. M. Jaiswal, N.F. LaRusso, L.J. Burgart, and G.J. Gores Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism Cancer Res 60 1 2000 184 190
88. A. Dhar, M.R. Young, and N.H. Colburn The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive Mol Cell Biochem 234/235 1/2 2002 185 193
89. C.H. Arnott, K.A. Scott, R.J. Moore, A. Hewer, D.H. Phillips, and P. Parker Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway Oncogene 21 31 2002 4728 4738
90. H. Korner, E. Cretney, P. Wilhelm, J.M. Kelly, M. Rollinghoff, and J.D. Sedgwick Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype J Exp Med 191 1 2000 89 96
91. C.H. Arnott, K.A. Scott, R.J. Moore, S.C. Robinson, R.G. Thompson, and F.R. Balkwill Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development Oncogene 23 10 2004 1902 1910
92. B. Knight, G.C. Yeoh, K.L. Husk, T. Ly, L.J. Abraham, and C. Yu Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice J Exp Med 192 12 2000 1809 1818
93. P. Orosz, B. Echtenacher, W. Falk, J. Ruschoff, D. Weber, and D.N. Mannel Enhancement of experimental metastasis by tumor necrosis factor J Exp Med 177 5 1993 1391 1398
94. A.M. Waterston, F. Salway, E. Andreakos, D.M. Butler, M. Feldmann, and R.C. Coombes TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model Br J Cancer 90 6 2004 1279 1284
95. H. Kitakata, Y. Nemoto-Sasaki, Y. Takahashi, T. Kondo, M. Mai, and N. Mukaida Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells Cancer Res 62 22 2002 6682 6687
96. S.T. Malik, M.S. Naylor, N. East, A. Oliff, and F.R. Balkwill Cells secreting tumour necrosis factor show enhanced metastasis in nude mice Eur J Cancer 26 10 1990 1031 1034
97. Z. Qin, S. Kruger-Krasagakes, U. Kunzendorf, H. Hock, T. Diamantstein, and T. Blankenstein Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis J Exp Med 178 1 1993 355 360
98. T.M. Leber, and F.R. Balkwill Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF) Br J Cancer 78 6 1998 724 732
99. E. Katerinaki, G.S. Evans, P.C. Lorigan, and S. MacNeil TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes Br J Cancer 89 6 2003 1123 1129
100. L.B. Nabors, E. Suswam, Y. Huang, X. Yang, M.J. Johnson, and P.H. King Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR Cancer Res 63 14 2003 4181 4187
101. I.B. Joseph, and J.T. Isaacs Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents J Natl Cancer Inst 90 21 1998 1648 1653
102. M. Nesbit, H. Schaider, T.H. Miller, and M. Herlyn Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells J Immunol 166 11 2001 6483 6490
103. S. Yoshida, M. Ono, T. Shono, H. Izumi, T. Ishibashi, and H. Suzuki Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis Mol Cell Biol 17 7 1997 4015 4023
104. N. Cheng, and J. Chen Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism J Biol Chem 276 17 2001 13771 13777
105. P. De Cesaris, D. Starace, G. Starace, A. Filippini, M. Stefanini, and E. Ziparo Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression J Biol Chem 274 41 1999 28978 28982
106. N. Kawai, S. Tsuji, M. Tsujii, T. Ito, M. Yasumaru, and Y. Kakiuchi Tumor necrosis factor alpha stimulates invasion of Src-activated intestinal cells Gastroenterology 122 2 2002 331 339
107. G. Mantovani, A. Maccio, P. Lai, E. Massa, M. Ghiani, and M.C. Santona Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Semin Oncol 25 2 Suppl. 6 1998 45 52
108. I. Dalum, D.M. Butler, M.R. Jensen, P. Hindersson, L. Steinaa, and A.M. Waterston Therapeutic antibodies elicited by immunization against TNF-alpha Nat Biotechnol 17 7 1999 666 669
109. P.A. Haslett Anticytokine approaches to the treatment of anorexia and cachexia Semin Oncol 25 2 Suppl. 6 1998 53 57
110. M.J. Tisdale Cancer cachexia Langenbecks Arch Surg 389 4 2004 299 305
111. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 12 2004 2312 2316
112. C. Dosquet, M.C. Coudert, E. Lepage, J. Cabane, and F. Richard Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 3 12 Pt 1 1997 2451 2458
113. K. Warzocha, J. Bienvenu, P. Ribeiro, I. Moullet, C. Dumontet, and E.M. Neidhardt-Berard Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients Br J Cancer 77 12 1998 2357 2362
114. K. Dredge, J.B. Marriott, and A.G. Dalgleish Immunological effects of thalidomide and its chemical and functional analogs Crit Rev Immunol 22 5-6 2002 425 437
115. R.J. D'Amato, S. Lentzsch, K.C. Anderson, and M.S. Rogers Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma Semin Oncol 28 6 2001 597 601
116. H.P. Marsh, N.A. Haldar, M. Bunce, S.E. Marshall, K. le Monier, and S.L. Winsey Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation Br J Cancer 89 6 2003 1096 1101
117. K. Nakajima, M. Sasaki, D. Nojima, B.R. Oh, N. Ishii, and K. Miura Tumor necrosis factor-alpha gene mutations and genotype changes in renal cell carcinoma J Urol 165 2 2001 612 615
118. B.R. Oh, M. Sasaki, G. Perinchery, S.B. Ryu, Y.I. Park, and P. Carroll Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer J Urol 163 5 2000 1584 1587
119. A.H. Hajeer, J.T. Lear, W.E. Ollier, M. Naves, J. Worthington, and D.A. Bell Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas Br J Dermatol 142 3 2000 441 445
120. S.Y. Ho, Y.J. Wang, H.L. Chen, C.H. Chen, C.J. Chang, and P.J. Wang Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene Cancer Causes Control 15 7 2004 657 663
121. J.C. Machado, C. Figueiredo, P. Canedo, P. Pharoah, R. Carvalho, and S. Nabais A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma Gastroenterology 125 2 2003 364 371
122. S. Mestiri, N. Bouaouina, S.B. Ahmed, A. Khedhaier, B.B. Jrad, and S. Remadi Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma Cancer 91 4 2001 672 678
123. K. Tsukasaki, C.W. Miller, T. Kubota, S. Takeuchi, T. Fujimoto, and S. Ikeda Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers Cancer Res 61 9 2001 3770 3774
124. F.E. Davies, S.J. Rollinson, A.C. Rawstron, E. Roman, S. Richards, and M. Drayson High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment J Clin Oncol 18 15 2000 2843 2851
125. K. Warzocha, P. Ribeiro, J. Bienvenu, P. Roy, C. Charlot, and D. Rigal Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome Blood 91 10 1998 3574 3581
126. S. Takeuchi, N. Takeuchi, K. Tsukasaki, C.R. Bartram, M. Zimmermann, and M. Schrappe Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia Br J Haematol 119 4 2002 985 987
127. H.C. Wu, C.H. Chang, H.Y. Chen, F.J. Tsai, J.J. Tsai, and W.C. Chen p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer Urol Int 73 1 2004 41 46
128. I.A. Azmy, S.P. Balasubramanian, A.G. Wilson, T.J. Stephenson, A. Cox, and N.J. Brown Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity Breast Cancer Res 6 4 2004 R395 R400
129. W.H. Jang, Y.I. Yang, S.S. Yea, Y.J. Lee, J.H. Chun, and H.I. Kim The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers Cancer Lett 166 1 2001 41 46
130. M.S. Wu, L.T. Chen, C.T. Shun, S.P. Huang, H.M. Chiu, and H.P. Wang Promoter polymorphisms of tumor necrosis factor-alpha are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma Int J Cancer 110 5 2004 695 700
131. C.R. Rossi, M. Foletto, P. Pilati, S. Mocellin, and M. Lise Isolated limb perfusion in locally advanced cutaneous melanoma Semin Oncol 29 4 2002 400 409
132. C.R. Rossi, S. Mocellin, P. Pilati, M. Foletto, D. Nitti, and M. Lise TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends J Immunother 26 4 2003 291 300
133. D. Christoforidis, O. Martinet, F.J. Lejeune, and F. Mosimann Isolated liver perfusion for non-resectable liver tumours: a review Eur J Surg Oncol 28 8 2002 875 890
134. J. Vilcek, and M. Feldmann Historical review: cytokines as therapeutics and targets of therapeutics Trends Pharmacol Sci 25 4 2004 201 209
135. K. Kajiwara, A. Saito, S. Ogata, and M. Tanihara Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively Biochim Biophys Acta 1699 1 2004 131 137
136. N.J. Olsen, and C.M. Stein New drugs for rheumatoid arthritis N Engl J Med 350 21 2004 2167 2179
137. S.L. Brown, M.H. Greene, S.K. Gershon, E.T. Edwards, and M.M. Braun Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 46 12 2002 3151 3158
138. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 50 6 2004 1740 1751
139. P.W. Szlosarek, and F.R. Balkwill Tumour necrosis factor alpha: a potential target for the therapy of solid tumours Lancet Oncol 4 9 2003 565 573
140. A.M. Tsimberidou, T. Waddelow, H.M. Kantarjian, M. Albitar, and F.J. Giles Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment Leuk Res 27 5 2003 375 380
141. J.S. Du Bois, E.G. Trehu, J.W. Mier, L. Shapiro, M. Epstein, and M. Klempner Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma J Clin Oncol 15 3 1997 1052 1062
142. X. Van Ostade, P. Vandenabeele, B. Everaerdt, H. Loetscher, R. Gentz, and M. Brockhaus Human TNF mutants with selective activity on the p55 receptor Nature 361 6409 1993 266 269
143. P. Ameloot, and P. Brouckaert Production and characterization of receptor-specific TNF muteins Methods Mol Med 98 2004 33 46
144. T. Sato, N. Yamauchi, H. Sasaki, M. Takahashi, T. Okamoto, and S. Sakamaki An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration Cancer Res 58 8 1998 1677 1683
145. S.J. Terlikowski Local immunotherapy with rhTNF-alpha mutein induces strong antitumor activity without overt toxicity: a review Toxicology 174 3 2002 143 152
146. S. Novakovic, V. Menart, V. Gaberc-Porekar, A. Stalc, G. Sersa, and M. Cemazar New TNF-alpha analogues: a powerful but less toxic biological tool against tumours Cytokine 9 8 1997 597 604
147. B. Wielockx, K. Lannoy, S.D. Shapiro, T. Itoh, S. Itohara, and J. Vandekerckhove Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy Nat Med 7 11 2001 1202 1208
148. P. Hohenberger, E. Latz, C. Kettelhack, A.H. Rezaei, R. Schumann, and P.M. Schlag Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan Ann Surg Oncol 10 5 2003 562 568
149. P. Jacquet, and P.H. Sugarbaker Peritoneal-plasma barrier Cancer Treat Res 82 1996 53 63
150. C.R. Rossi, S. Mocellin, P. Pilati, M. Foletto, L. Quintieri, and P. Palatini Pharmacokinetics of intraperitoneal cisplatin and doxorubicin Surg Oncol Clin N Am 12 3 2003 781 794
151. W. Behammer, M. Kluge, J. Ruschoff, and D.N. Mannel Tumor necrosis factor effects on ascites formation in an experimental tumor model J Interferon Cytokine Res 16 5 1996 403 408
152. M. Gutman, D. Sofer, D. Lev-Chelouche, O. Merimsky, and J.M. Klausner Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study Invasion Metastasis 17 4 1997 169 175
153. D.L. Bartlett, J.F. Buell, S.K. Libutti, E. Reed, K.B. Lee, and W.D. Figg A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis Cancer 83 6 1998 1251 1261
154. T.L. ten Hagen, A.L. Seynhaeve, S.T. van Tiel, D.J. Ruiter, and A.M. Eggermont Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats Int J Cancer 97 1 2002 115 120
155. P. Brouckaert, N. Takahashi, S.T. van Tiel, J. Hostens, A.M. Eggermont, and A.L. Seynhaeve Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics Int J Cancer 109 3 2004 442 448
156. R.R. Weichselbaum, D.W. Kufe, S. Hellman, H.S. Rasmussen, C.R. King, and P.H. Fischer Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy Lancet Oncol 3 11 2002 665 671
157. N. Senzer, S. Mani, A. Rosemurgy, J. Nemunaitis, C. Cunningham, and C. Guha TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors J Clin Oncol 22 4 2004 592 601
158. F. Bazzoni, and E. Regalia Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha Cancer Res 61 3 2001 1050 1057
159. C.W. Xiao, X. Yan, Y. Li, S.A. Reddy, and B.K. Tsang Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein Endocrinology 144 2 2003 623 630
160. K.M. Vasudevan, S. Gurumurthy, and V.M. Rangnekar Suppression of PTEN expression by NF-kappa B prevents apoptosis Mol Cell Biol 24 3 2004 1007 1021
161. R.M. Zwacka, L. Stark, and M.G. Dunlop NF-kappaB kinetics predetermine TNF-alpha sensitivity of colorectal cancer cells J Gene Med 2 5 2000 334 343
162. C.Y. Wang, J.C. Cusack Jr., R. Liu, and A.S. Baldwin Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB Nat Med 5 4 1999 412 417
163. K.Y. Lee, W. Chang, D. Qiu, P.N. Kao, and G.D. Rosen PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells J Biol Chem 274 19 1999 13451 13455
164. N.B. Davis, D.A. Taber, R.H. Ansari, C.W. Ryan, C. George, and E.E. Vokes Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study J Clin Oncol 22 1 2004 115 119
165. C.N. Papandreou, and C.J. Logothetis Bortezomib as a potential treatment for prostate cancer Cancer Res 64 15 2004 5036 5043
166. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, and D. Irwin A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2003 2609 2617
167. J. An, Y.P. Sun, J. Adams, M. Fisher, A. Belldegrun, and M.B. Rettig Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer Clin Cancer Res 9 12 2003 4537 4545
168. C. Binder, M. Schulz, W. Hiddemann, and M. Oellerich Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells Lab Invest 79 12 1999 1703 1712
169. Y. Kaku, H. Nanri, T. Sakimura, K. Ejima, A. Kuroiwa, and M. Ikeda Differential induction of constitutive and inducible nitric oxide synthases by distinct inflammatory stimuli in bovine aortic endothelial cells Biochim Biophys Acta 1356 1 1997 43 52
170. R.W. Ganster, B.S. Taylor, L. Shao, and D.A. Geller Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B Proc Natl Acad Sci USA 98 15 2001 8638 8643
171. W. Song, X. Lu, and Q. Feng Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes Cardiovasc Res 45 3 2000 595 602
172. Y.M. Kim, R.V. Talanian, and T.R. Billiar Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms J Biol Chem 272 49 1997 31138 31148
173. S. Dimmeler, J. Haendeler, M. Nehls, and A.M. Zeiher Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases J Exp Med 185 4 1997 601 607
174. Y.M. Kim, T.H. Kim, D.W. Seol, R.V. Talanian, and T.R. Billiar Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release J Biol Chem 273 47 1998 31437 31441
175. J. Li, C.A. Bombeck, S. Yang, Y.M. Kim, and T.R. Billiar Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes J Biol Chem 274 24 1999 17325 17333
176. N.J. Torok, H. Higuchi, S. Bronk, and G.J. Gores Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9 Cancer Res 62 6 2002 1648 1653
177. W.J. Thomas, D.L. Thomas, J.A. Knezetic, and T.E. Adrian The role of oxygen-derived free radicals and nitric oxide in cytokine-induced antiproliferation of pancreatic cancer cells Pancreas 24 2 2002 161 168
178. S. Bulotta, R. Barsacchi, D. Rotiroti, N. Borgese, and E. Clementi Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha: a novel feedback mechanism regulating cell death J Biol Chem 276 9 2001 6529 6536
179. J.H. de Wilt, E.R. Manusama, B. van Etten, S.T. van Tiel, A.S. Jorna, and A.L. Seynhaeve Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions Br J Cancer 83 9 2000 1176 1182
180. Y.A. Hannun, and C. Luberto Ceramide in the eukaryotic stress response Trends Cell Biol 10 2 2000 73 80
181. H.J. Garban, and B. Bonavida Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha-induced cytotoxicity J Biol Chem 276 12 2001 8918 8923
182. E. Obrador, J. Carretero, J.A. Pellicer, and J.M. Estrela Possible mechanisms for tumour cell sensitivity to TNF-alpha and potential therapeutic applications Curr Pharm Biotechnol 2 2 2001 119 130
183. R. Liu, B. Li, and M. Qiu Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha Oncogene 20 12 2001 1486 1496
184. S. Delhalle, V. Deregowski, V. Benoit, M.P. Merville, and V. Bours NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis Oncogene 21 24 2002 3917 3924
185. C. Giardina, H. Boulares, and M.S. Inan NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species Biochim Biophys Acta 1448 3 1999 425 438
186. K.S. Berman, U.N. Verma, G. Harburg, J.D. Minna, M.H. Cobb, and R.B. Gaynor Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB Clin Cancer Res 8 2 2002 354 360
187. G. Totzke, K. Schulze-Osthoff, and R.U. Janicke Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition Oncogene 22 39 2003 8021 8030
188. H. Yasui, M. Adachi, and K. Imai Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice Cancer 97 6 2003 1412 1420
189. S. Fulda, and K.M. Debatin IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway Oncogene 21 15 2002 2295 2308
190. D. Lienard, A.M. Eggermont, H.S. Koops, B. Kroon, G. Towse, and S. Hiemstra Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study Melanoma Res 9 5 1999 491 502
191. A.M. Eggermont, H. Schraffordt Koops, J.M. Klausner, B.B. Kroon, P.M. Schlag, and D. Lienard Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann Surg 224 6 1996 756 764 discussion 764-765.
192. M.F. Gnant, A.C. Berger, J. Huang, M. Puhlmann, P.C. Wu, and M.J. Merino Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus Cancer Res 59 18 1999 4668 4674
193. A.C. Berger, H.R. Alexander, P.C. Wu, G. Tang, M.F. Gnant, and A. Mixon Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II) Cytokine 12 7 2000 992 1000
194. V. Chopin, C. Slomianny, H. Hondermarck, and X. Le Bourhis Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1) Exp Cell Res 298 2 2004 560 573
195. V. Duverger, A.M. Murphy, D. Sheehan, K. England, T.G. Cotter, and I. Hayes The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) Br J Cancer 90 10 2004 2025 2031
196. R. Beyaert, B. Vanhaesebroeck, P. Suffys, F. Van Roy, and W. Fiers Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo Proc Natl Acad Sci USA 86 23 1989 9494 9498
197. P. Schotte, G. Van Loo, I. Carpentier, P. Vandenabeele, and R. Beyaert Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein J Biol Chem 276 28 2001 25939 25945
198. M. Hanada, J. Feng, and B.A. Hemmings Structure, regulation and function of PKB/AKT: a major therapeutic target Biochim Biophys Acta 1697 1/2 2004 3 16
199. M. Diarra-Mehrpour, S. Arrabal, A. Jalil, X. Pinson, C. Gaudin, and G. Pietu Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death Cancer Res 64 2 2004 719 727
200. L. Zhang, T. Himi, I. Morita, and S. Murota Inhibition of phosphatidylinositol-3 kinase/Akt or mitogen-activated protein kinase signaling sensitizes endothelial cells to TNF-alpha cytotoxicity Cell Death Differ 8 5 2001 528 536
201. S. Nishida, S. Yoshioka, S. Kinoshita-Kimoto, M. Kotani, M. Tsubaki, and Y. Fujii Pretreatment with PKC inhibitor triggers TNF-alpha induced apoptosis in TNF-alpha-resistant B16 melanoma BL6 cells Life Sci 74 6 2003 781 792
202. M. Bezzi, M. Hasmim, G. Bieler, O. Dormond, and C. Ruegg Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt J Biol Chem 278 44 2003 43603 43614
203. M. Leist, and M. Jaattela Burning up TNF toxicity for cancer therapy Nat Med 8 7 2002 667 668
204. S. Greenberger, A. Shaish, N. Varda-Bloom, K. Levanon, E. Breitbart, and I. Goldberg Transcription-controlled gene therapy against tumor angiogenesis J Clin Invest 113 7 2004 1017 1024
205. L. Li, R.M. Thomas, H. Suzuki, J.K. De Brabander, X. Wang, and P.G. Harran A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death Science 305 5689 2004 1471 1474
206. G.M. Anderson, M.T. Nakada, and M. DeWitte Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer Curr Opin Pharmacol 4 4 2004 314 320
207. Y. Tada, J. Ow, K. Takenaga, Y. Takiguchi, K. Tatsumi, and T. Kuriyama Expression of the TNF-alpha gene on mouse lung carcinoma cells suppresses spontaneous lung metastasis without affecting tumorigenicity Oncol Rep 9 3 2002 585 588
208. A.L. Ortega, J. Carretero, E. Obrador, J. Gambini, M. Asensi, and V. Rodilla Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium J Biol Chem 278 16 2003 13888 13897
209. D. Lienard, A.M. Eggermont, H. Schraffordt Koops, B.B. Kroon, F. Rosenkaimer, and P. Autier Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study Melanoma Res 4 Suppl. 1 1994 21 26
210. D.L. Fraker, H.R. Alexander, M. Andrich, and S.A. Rosenberg Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study J Clin Oncol 14 2 1996 479 489
211. C.R. Rossi, M. Foletto, S. Mocellin, P. Pilati, and M. Lise Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases Ann Surg Oncol 11 2 2004 173 177
212. M. Gutman, M. Inbar, D. Lev-Shlush, S. Abu-Abid, M. Mozes, and S. Chaitchik High-dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation Cancer 79 6 1997 1129 1137
213. B.E. Plaat, W.M. Molenaar, M.F. Mastik, J. Koudstaal, E. van den Berg, and H.S. Koops Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis Clin Cancer Res 5 7 1999 1650 1657
214. C.R. Rossi, M. Foletto, F. Di Filippo, M. Vaglini, M. Anza, and A. Azzarelli Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion Cancer 86 9 1999 1742 1749
215. F.J. Lejeune, N. Pujol, D. Lienard, F. Mosimann, W. Raffoul, and A. Genton Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities Eur J Surg Oncol 26 7 2000 669 678
216. R. Komdeur, B.E. Plaat, H.J. Hoekstra, W.M. Molenaar, H. Hollema, and E. van den Berg Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan Cancer 91 10 2001 940 948
217. E.M. Noorda, B.C. Vrouenraets, O.E. Nieweg, F. van Coevorden, G.W. van Slooten, and B.B. Kroon Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities Cancer 98 7 2003 1483 1490
218. Rossi C, Mocellin C, Pilati P, Foletto M, Quintieri L, Desalvo G, et al. Hyperthermic isolated perfusion with low-dose TNFa and doxorubicin for the treatment of limb threatening soft tissue sarcomas: a phase II study. Ann Surg Oncol; in press.
219. H.R. Alexander, D.L. Bartlett, S.K. Libutti, D.L. Fraker, T. Moser, and S.A. Rosenberg Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver J Clin Oncol 16 4 1998 1479 1489
220. H.R. Alexander, S.K. Libutti, D.L. Bartlett, M. Puhlmann, D.L. Fraker, and L.C. Bachenheimer A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver Clin Cancer Res 6 8 2000 3062 3070
221. D.L. Bartlett, S.K. Libutti, W.D. Figg, D.L. Fraker, and H.R. Alexander Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer Surgery 129 2 2001 176 187
222. E.D. Feldman, P.C. Wu, T. Beresneva, C. Helsabeck, M. Rodriguez, and D.L. Bartlett Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion J Gastrointest Surg 8 2 2004 200 207